CGON
CG Oncology, Inc.
Key Financials
Operating Income
$-190774000
↓ 66.4%
Net Income
$-160995000
↓ 82.9%
EPS (Diluted)
$-2.08
↓ 47.5%
Total Liabilities
$39.0M
↑ 82.0%
Total Assets
$791.6M
↑ 4.9%
Shareholders' Equity
$752.6M
↑ 2.6%
Cash & Equivalents
$32.5M
↓ 87.4%
Operating Cash Flow
$-132346000.00
↓ 68.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 6/16/2026 | View on SEC |
| 8-K | 6/8/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 4 | 6/5/2026 | View on SEC |
| 144 | 6/4/2026 | View on SEC |
| 8-K | 5/26/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CGON |
| Company Name | CG Oncology, Inc. |
| CIK | 1991792 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (949) 409-3700 |